Annals of Oncology 13:689-698, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up
1Division of Medical Oncology, 2Pathology Department, 3Biometrics Department and 4Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Received 31 October 2001; revised 18 February 2002; accepted 8 March 2002.
Background
The aim of this study was to present an update of overall (OS) and disease-free survival (DFS) and to evaluate the correlation between outcome and pathological findings at surgery in a randomized trial of high-dose chemotherapy following neoadjuvant chemotherapy and surgery in high-risk breast cancer patients.
Patients and methods
Ninety-seven women <60 years of age with breast cancer and extensive axillary lymph node involvement received three courses of FE120C (5-fluorouracil 500 mg/m2, epirubicin 120 mg/m2, cyclophosphamide 500 mg/m2) followed by surgery. Eighty-one patients were randomized to receive either a fourth FE120C course alone or a fourth FE120C course followed by high-dose chemotherapy (cyclophosphamide 6 g/m2, thiotepa 480 mg/m2, carboplatin 1600 mg/m2). We performed a univariate analysis on possible prognostic factors and analyzed the sites of relapse.
Results
After a median follow-up of 6.9 years, 47 (48%) patients were alive, of whom 36 (38%) were without disease. Sixty patients relapsed after treatment. One patient died of myelodysplastic syndrome, without a relapse. In intention-to-treat analysis, the 5-year DFS rates were 47.5% in the conventional treatment arm and 49% in the high-dose arm, and the 5-year OS rates were 62.5% and 61%, respectively. In the univariate analysis, the clinical T-stage before chemotherapy and the number of tumor-positive axillary lymph nodes after induction chemotherapy (P = 0.027) were significant prognostic factors for OS. The same factors (both P = 0.06) plus the estrogen receptor (P = 0.08) were borderline significant factors for DFS.
Conclusions
After a median follow-up of 6.9 years there was no difference in OS or DFS rates between the two treatment groups. The number of tumor-positive axillary lymph nodes after induction chemotherapy and the clinical T-stage before chemotherapy were significant factors for OS.
Key words: breast cancer, hematopoietic progenitor-cell support, high-dose chemotherapy, randomized trial
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. R. Zander, C. Schmoor, N. Kroger, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. E. Berdel, M. Koenigsmann, E. Thiel, et al. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up Ann. Onc., June 1, 2008; 19(6): 1082 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Wilking, E Lidbrink, T Wiklund, B Erikstein, H Lindman, P Malmstrom, P Kellokumpu-Lehtinen, N-O Bengtsson, G Soderlund, G Anker, et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy Ann. Onc., April 1, 2007; 18(4): 694 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rodenhuis, M. Bontenbal, Q. G. C. M. van Hoesel, W. M. Smit, M. A. Nooij, E. E. Voest, E. van der Wall, P. Hupperets, H. van Tinteren, J. L. Peterse, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann. Onc., April 1, 2006; 17(4): 588 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 International Breast Cancer Study Group Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95 J. Clin. Oncol., January 20, 2006; 24(3): 370 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kroger, K. Milde-Langosch, S. Riethdorf, C. Schmoor, M. Schumacher, A. R. Zander, and T. Loning Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients Clin. Cancer Res., January 1, 2006; 12(1): 159 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schneeweiss, I. Diel, M. Hensel, S. Kaul, H.-P. Sinn, K. Unnebrink, C. Rudlowski, I. Lauschner, F. Schuetz, G. Egerer, et al. Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy Ann. Onc., November 1, 2004; 15(11): 1627 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Wild, A. Reichle, R. Andreesen, G. Rockelein, W. Dietmaier, J. Ruschoff, H. Blaszyk, F. Hofstadter, and A. Hartmann Microsatellite Instability Predicts Poor Short-Term Survival in Patients with Advanced Breast Cancer after High-Dose Chemotherapy and Autologous Stem-Cell Transplantation Clin. Cancer Res., January 15, 2004; 10(2): 556 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wheatley, R. G. Gray, N. J. Ives, A. Tartarone, G. Iodice, N. Di Renzo, M. M. Mangano, C. Dazzi, A. Cariello, S. Rodenhuis, et al. High-Dose Chemotherapy for Breast Cancer N. Engl. J. Med., October 9, 2003; 349(15): 1476 - 1479. [Full Text] [PDF]
|
|
|
|
|
|
M. Hensel, A. D. Ho, G. Bastert, and A. Schneeweiss Prognostic markers for survival after high-dose chemotherapy with autologous stem-cell transplantation for breast cancer Ann. Onc., February 1, 2003; 14(2): 341 - 341. [Full Text] [PDF]
|
|
|
|
|
|
E. Galani, P. A. Ellis, and P. G. Harper Small-Cell Lung Cancer, High Growth Rate, High Response Rate to Chemotherapy: Ideal for High-Dose Chemotherapy? J. Clin. Oncol., October 1, 2002; 20(19): 3941 - 3943. [Full Text] [PDF]
|
|
|
|
|
|
L. Gianni High-dose chemotherapy for breast cancer: any use for it? Ann. Onc., May 1, 2002; 13(5): 650 - 652. [Full Text] [PDF]
|
|